Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01644968 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01644968 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 30 participants.
The verdict
NCT01644968, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.
Interventions
- DRUG Cohort 1 anti-OX40
- DRUG Cohort 2 anti-OX40
- DRUG Cohort 3 anti-OX40
- BIOLOGICAL Tetanus Day 29
- BIOLOGICAL Tetanus Day 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01644968
The ClinicalTrials.gov registry entry for NCT01644968 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cohort 1 anti-OX40 is the first listed.
NCT01644968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01644968 about?
NCT01644968 is a clinical study titled "Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer". This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.
What is the current status of trial NCT01644968?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01644968?
The interventions under investigation include: Cohort 1 anti-OX40 (DRUG), Cohort 2 anti-OX40 (DRUG), Cohort 3 anti-OX40 (DRUG), Tetanus Day 29 (BIOLOGICAL), Tetanus Day 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01644968?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.